Work

NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.tps603

Authors: Charles E. Geyer, Sibylle Loibl, Priya Rastogi, Sabine Seiler, Joseph P. Costantino, Namrata Vijayvergia, Patricia Cortazar, Peter C. Lucas, Carsten Denkert, Eleftherios P. Mamounas, Christian Jackisch, Norman Wolmark

Institutions: NRG Oncology, VCU Massey Comprehensive Cancer Center, German Breast Group, Magee-Womens Hospital, University of Pittsburgh, Fox Chase Cancer Center, American College of Radiology Imaging Network, Genentech, Charité – Universitätsmedizin Berlin, Orlando Health, Sana Klinikum Offenbach, Allegheny Health Network

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2805572555

Cites:

Cited by: 14

Related to: 10